FI119451B - Screening av graviditetsavvikelser före födseln - Google Patents

Screening av graviditetsavvikelser före födseln Download PDF

Info

Publication number
FI119451B
FI119451B FI953830A FI953830A FI119451B FI 119451 B FI119451 B FI 119451B FI 953830 A FI953830 A FI 953830A FI 953830 A FI953830 A FI 953830A FI 119451 B FI119451 B FI 119451B
Authority
FI
Finland
Prior art keywords
syndrome
dimeric
probability
inhibin
hcg
Prior art date
Application number
FI953830A
Other languages
English (en)
Finnish (fi)
Other versions
FI953830A0 (sv
FI953830A (sv
Inventor
Andrew Jonathan Beard
Adrian Charles Dawkes
Christopher John Davies
Original Assignee
Ortho Clinical Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Clinical Diagnostics Inc filed Critical Ortho Clinical Diagnostics Inc
Publication of FI953830A0 publication Critical patent/FI953830A0/sv
Publication of FI953830A publication Critical patent/FI953830A/sv
Application granted granted Critical
Publication of FI119451B publication Critical patent/FI119451B/sv

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/76—Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G01N2800/385—Congenital anomalies
    • G01N2800/387—Down syndrome; Trisomy 18; Trisomy 13
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y10S436/817—Steroids or hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Medical Informatics (AREA)
  • Reproductive Health (AREA)
  • Public Health (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Fire Alarms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Claims (5)

1. Förfarande för att utvärdera riskerna för kro-mosomal avvikelse hos ett foster före födseln, kanne-5 tecknat av att man A) utvärderar den gravida patientens primära risk att förbära ett foster, som har nämnda kromosomala avvikelse, B) mäter koncentrationen av dimert inhibin i den 10 nämnda gravida patientens blod, C) räknar ut det normaliserade värdet för nämnda koncentration genom att dela nämnda koncentration med ett medianvärde, som erhällits hos en kvinnopopulation med normal graviditet och samma graviditetstid som nämnda gra- 15 vida patient, D) räknar ut en första sannolikhet för att det korrigerade, normaliserade värdet är en del av en Gauss-fördelning som erhällits i normala graviditeter, E) räknar ut en andra sannolikhet för att det kor-20 rigerade, normaliserade värdet är en del av en Gauss- fördelning som erhällits i graviditeter med nämnda kromo- • · · ϊ ί somala avvikelse, «·· ' :1·1: F) räknar ut ett sannolikhetsförhällande, som är • · ·1;1; nämnda första sannolikhet dividerad med nämnda andra san- • · 25 nolikhet, och • 1 • · • .·, G) modifierar den tidigare risken med sannolik- *♦!.1 hetsförhällandet. • · φ
• · · * 2. Förfarande enligt patentkrav 1, känneteck- . , nat av att man i steg B) i nämnda blodprov frän patienten • « · *·’·1 30 dessutom mäter koncentrationen av ett märkämne, vilket är ··· *...· intakt hCG, alfafetoprotein eller okonjugerad estriol. «
3. Förfarande enligt patentkrav 1, känneteck- • · .··1. nat av att den kromosomala avvikelsen är Downs syndrom, • · • · 1 t1 t trisomi 18, trisomi 13 eller Turners syndrom. « · · • M • · · • · · • ·· • · 119451
4. Förfarande enligt patentkrav 2, känneteck-nat av att den kromosomala avvikelsen är Downs syndrom, trisomi 18, trisomi 13 eller Turners syndrom.
5. Anordning, kännetecknad av att den inne-5 hcLller medel för att erhälla mätt pä dimert inhibin i en gravid patients blod och en dator, som är programmerad för att utföra förfarandet enligt patentkrav 1 för att utvär-dera riskerna före födseln. ··· • · • · ·· ·· 1 • < · • · • · • · • · m • · · • · ·· · • t · • · • · • · f · 1 • · 1 ··· · ♦ ·· « · 1 • · · ♦ · • · · » · • · ·1« * · • · ··« • · • · · • · · • · ··· t · • 1 ··· • · • ♦ · • ·· • f · • · · • ♦ · • ·
FI953830A 1994-08-13 1995-08-11 Screening av graviditetsavvikelser före födseln FI119451B (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9416415A GB9416415D0 (en) 1994-08-13 1994-08-13 Antenatel screening for pregnacy abnormalities
GB9416415 1994-08-13

Publications (3)

Publication Number Publication Date
FI953830A0 FI953830A0 (sv) 1995-08-11
FI953830A FI953830A (sv) 1996-02-14
FI119451B true FI119451B (sv) 2008-11-14

Family

ID=10759858

Family Applications (1)

Application Number Title Priority Date Filing Date
FI953830A FI119451B (sv) 1994-08-13 1995-08-11 Screening av graviditetsavvikelser före födseln

Country Status (10)

Country Link
US (1) US6022695A (sv)
EP (1) EP0701131B1 (sv)
JP (1) JP3626251B2 (sv)
KR (1) KR100389988B1 (sv)
AT (1) ATE213334T1 (sv)
AU (1) AU698204B2 (sv)
CA (1) CA2155919C (sv)
DE (1) DE69525400T2 (sv)
FI (1) FI119451B (sv)
GB (1) GB9416415D0 (sv)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606261D0 (en) * 1996-03-25 1996-05-29 Johnson & Johnson Clin Diag Prenatal screening for fetal abnormalities
US6620590B2 (en) 1996-07-11 2003-09-16 Isis Innovation Limited Diagnosis of pre-eclampsia
GB9614615D0 (en) * 1996-07-11 1996-09-04 Isis Innovation Diagnosis of pre-eclampsia
CA2486089C (en) 2002-05-15 2013-12-17 Tommy J. Morris System and method for handling medical information
US20050131738A1 (en) * 2002-05-15 2005-06-16 Morris Tommy J. System and method for handling medical information
US7315787B2 (en) * 2003-10-07 2008-01-01 Ntd Laboratories, Inc. Multi-marker screening protocol for fetal abnormalities
JP2007521854A (ja) * 2003-12-02 2007-08-09 シュレイガ ロッテム 母体−胎児状態の診断、スクリーニング、予防、及び治療のための人工知能及び装置
US20070249531A1 (en) * 2004-02-20 2007-10-25 Aplagen Gmbh Method for the Detection of Autoantibodies Against Specific Peptides and Its Use in Diagnosis and Treatment of Pregnancy-Loss or Infertility
ATE538217T1 (de) * 2007-07-02 2012-01-15 Univ Edinburgh Erkennung von ektopischen schwangerschaften
US20100027571A1 (en) * 2008-07-31 2010-02-04 Murdoch Keith M Stabilized near-infrared laser
WO2011144999A1 (en) 2010-05-17 2011-11-24 Sandra Reznik Plasma protein-a2 (papp-a2) as a marker for detecting risk of chromosomal abnormalities

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4874693A (en) * 1986-10-10 1989-10-17 Mark Bogart Method for assessing placental dysfunction
ATE91182T1 (de) * 1987-07-09 1993-07-15 3I Res Expl Ltd Praenatales screening fuer downs-syndrom.
GB8816714D0 (en) * 1988-07-14 1988-08-17 Univ Court Of University Of Gl Switched reluctance motors
ATE252240T1 (de) * 1989-01-17 2003-11-15 Jn Macri Technologies Llc Inc Einrichtung zum nachweis vom down syndrom durch nichtinvasive siebtestung des mütterlichen blutes
GB9224965D0 (en) * 1992-11-28 1993-01-20 Kodak Ltd Antenatal screening for chromosomal abnormalities
GB9410345D0 (en) * 1994-05-24 1994-07-13 Univ Oxford Brookes Method of genetic testing
US5716853A (en) * 1995-07-07 1998-02-10 Chiron Diagnostics Corporation Prenatal down syndrome screening with assays specific for UGP

Also Published As

Publication number Publication date
KR100389988B1 (ko) 2003-12-06
DE69525400T2 (de) 2002-07-18
JPH09113508A (ja) 1997-05-02
GB9416415D0 (en) 1994-10-05
US6022695A (en) 2000-02-08
ATE213334T1 (de) 2002-02-15
EP0701131A2 (en) 1996-03-13
FI953830A0 (sv) 1995-08-11
DE69525400D1 (de) 2002-03-21
CA2155919A1 (en) 1996-02-14
KR960008312A (ko) 1996-03-22
EP0701131B1 (en) 2002-02-13
FI953830A (sv) 1996-02-14
AU698204B2 (en) 1998-10-29
JP3626251B2 (ja) 2005-03-02
EP0701131A3 (en) 1996-05-29
CA2155919C (en) 2007-06-05
AU2848795A (en) 1996-02-29

Similar Documents

Publication Publication Date Title
Wald et al. Maternal serum unconjugated oestriol as an antenatal screening test for Down's syndrome
Spencer et al. Maternal serum free β‐hCG and PAPP‐A in fetal sex chromosome defects in the first trimester
Spencer et al. Screening for trisomy 13 by fetal nuchal translucency and maternal serum free β‐hCG and PAPP‐A at 10–14 weeks of gestation
Wald et al. Four‐marker serum screening for Down's syndrome
Spencer Evaluation of an assay of the free beta-subunit of choriogonadotropin and its potential value in screening for Down's syndrome
CA2330538C (en) Antenatal screening for down&#39;s syndrome
US20100120076A1 (en) Method for antenatal estimation of risk of aneuploidy
Canick et al. Second trimester serum markers
Wald et al. The use of free β‐hCG in antenatal screening for Down's syndrome
FI119451B (sv) Screening av graviditetsavvikelser före födseln
Cole et al. Urinary screening tests for fetal Down syndrome: II. Hyperglycosylated hCG
Wenstrom et al. α-Fetoprotein, free β-human chorionic gonadotropin, and dimeric inhibin A produce the best results in a three-analyte, multiple-marker screening test for fetal Down syndrome
Petrocik et al. Prenatal screening for Down syndrome with maternal serum human chorionic gonadotropin levels
Cole et al. Hyperglycosylated hCG, a potential alternative to hCG in Down syndrome screening
US6010912A (en) Antenatal screening for chromosomal abnormalities
Palomaki et al. A summary analysis of Down syndrome markers in the late first trimester
KR0171451B1 (ko) 비관혈적인 임산부 혈액 검색에 의해 다운 증후군을 검출하는 방법 및 장치
JP2005246080A (ja) 染色体異常を出生前に評価する装置
Gong et al. Free thyroxine reference interval in each trimester of pregnancy determined with the Roche Modular E-170 electrochemiluminescent immunoassay
JPH03502483A (ja) 胎児のダウン症候群を検出する方法およびその装置
Lee et al. Performance characteristics of the UniCel DxI 800 immunoassay for the maternal serum quadruple test, including median values for each week of gestation, in Korean women
Spencer Screening for Down's syndrome. The role of intact hCG and free subunit measurement
Lambert‐Messerlian et al. Early onset preeclampsia and second trimester serum markers
Bahado-Singh et al. Comparison of urinary hyperglycosylated human chorionic gonadotropin concentration with the serum triple screen for Down syndrome detection in high-risk pregnancies
France et al. Serum concentrations of human chorionic Gonadotrophs and Immunoreactive inhibin in early pregnancy and recurrent miscarriage: a longitudinal study

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: ORTHO-CLINICAL DIAGNOSTICS, INC.

Free format text: ORTHO-CLINICAL DIAGNOSTICS, INC.

FG Patent granted

Ref document number: 119451

Country of ref document: FI

MA Patent expired